-
Ind-Swift Ltd Q3FY23 Results: Net Profit Rises 55% to Rs 86.74 Cr
Ind-Swift Ltd has reported a 55% increase in its net profit to Rs 86.74 crore for the third quarter of the financial year 2022-23 (Q3FY23), as compared to Rs 56.02 crore in the corresponding quarter of the previous fiscal.
-
Ind-Swift Ltd Partners with Pernod Ricard India to Distribute Select Portfolio of Whiskies
Ind-Swift Ltd has entered into a partnership with Pernod Ricard India to distribute a select portfolio of whiskies in India. Under the terms of the agreement, Ind-Swift will distribute Pernod Ricard India's Imperial Blue, Royal Stag, Blenders Pride, and 100 Pipers whiskies in select markets across India.
-
Ind-Swift Ltd Launches New Campaign for its Whisky Brand, 'Officer's Choice'
Ind-Swift Ltd has launched a new campaign for its whisky brand, 'Officer's Choice', featuring Bollywood actor Ajay Devgn. The campaign is aimed at highlighting the brand's strong association with the Indian armed forces and its commitment to providing quality products to consumers.
-
Ind-Swift Ltd. Q3FY23 Results: Net Profit Rises 13.5% YoY to Rs 123.15 Crore
Ind-Swift Ltd. has reported a 13.5% year-on-year (YoY) increase in its net profit to Rs 123.15 crore for the third quarter of the financial year 2023 (Q3FY23). The company's revenue from operations also grew by 11.7% YoY to Rs 930.94 crore during the quarter under review.
-
Ind-Swift Ltd. Partners with Jubilant Pharmova to Market and Distribute NCEs in India
Ind-Swift Ltd. has entered into a strategic partnership with Jubilant Pharmova Limited to market and distribute new chemical entities (NCEs) in India. Under the terms of the agreement, Ind-Swift will leverage its extensive distribution network to market and distribute Jubilant's NCEs in India.
-
Ind-Swift Ltd. Receives US FDA Approval for Abbreviated New Drug Application (ANDA) of Montelukast Sodium Tablets
Ind-Swift Ltd. has announced that it has received approval from the United States Food and Drug Administration (US FDA) for its Abbreviated New Drug Application (ANDA) of Montelukast Sodium Tablets, 10 mg. Montelukast Sodium Tablets are indicated for the treatment of asthma and seasonal allergic rhinitis.
-
Ind-Swift Ltd. announces Q3 FY23 results, reports revenue growth of 10%
Ind-Swift Ltd., a leading manufacturer of pharmaceutical formulations and active pharmaceutical ingredients (APIs), today announced its financial results for the third quarter (Q3) of fiscal year 2023 (FY23). The company reported a revenue growth of 10% year-over-year (YoY) to Rs. 721.4 crore in Q3 FY23, as compared to Rs. 656.3 crore in Q3 FY22.
-
Ind-Swift Ltd. receives US FDA approval for its generic version of Lipitor, a cholesterol-lowering drug
Ind-Swift Ltd., a leading manufacturer of pharmaceutical formulations and active pharmaceutical ingredients (APIs), today announced that it has received approval from the United States Food and Drug Administration (US FDA) for its abbreviated new drug application (ANDA) for Atorvastatin Calcium Tablets, the generic version of Pfizer's Lipitor, a cholesterol-lowering drug.
-
Ind-Swift Ltd. launches new manufacturing facility in Visakhapatnam, India
Ind-Swift Ltd., a leading manufacturer of pharmaceutical formulations and active pharmaceutical ingredients (APIs), today announced the launch of its new state-of-the-art manufacturing facility in Visakhapatnam, Andhra Pradesh, India. The new facility will produce a range of pharmaceutical products, including tablets, capsules, and injectables.
-
India Food Forum 2023: Ind-Swift to showcase new products and technologies
Ind-Swift Ltd., leading manufacturer of branded basmati rice, spices, and other food products, will be participating in the upcoming India Food Forum (IFF) 2023, to be held from February 14-16, 2023, at the India Expo Mart, Greater Noida.
-
Ind-Swift Ltd. Q3FY23 Results: Revenue up 23%, Profit up 37%
Ind-Swift Ltd., one of the leading players in the branded basmati rice segment, has declared its financial results for the third quarter (Q3) of the financial year 2022-23 (FY23). The company reported strong revenue and profit growth during the quarter.
-
Ind-Swift Ltd. Declares Fourth Interim Dividend for FY2023
The Board of Directors of Ind-Swift Limited has declared a fourth interim dividend of Rs. 0.60 per equity share (face value of Rs. 10 each) for the financial year 2022-23. The record date for the purpose of determining the eligibility of shareholders for the dividend is March 22, 2023.
-
Ind-Swift Ltd. Reports Net Profit Growth of 23% in Q3 FY2023
Ind-Swift Limited has reported a 23% growth in its net profit to Rs. 101.97 crores for the third quarter of the financial year 2022-23, as compared to Rs. 83.03 crores in the same period of the previous financial year. The company's total revenue for the quarter increased by 16% to Rs. 1,245.66 crores.
-
Ind-Swift Ltd. Launches New Range of Alcoholic Beverages in Rajasthan
Ind-Swift Limited has expanded its product portfolio in Rajasthan with the launch of a new range of alcoholic beverages, including whiskey, rum, and vodka. The company has invested Rs. 100 crores in setting up a new bottling plant in the state.
-
Ind-Swift Ltd Q4 net profit declines 22% to Rs 18 crore
Ind-Swift Ltd on Saturday reported a 21.94 per cent decline in its consolidated net profit to Rs 17.98 crore for the fourth quarter ended March 2023.
-
Ind-Swift Ltd's net profit rises 11% to Rs 64 crore in FY23
Drug firm Ind-Swift Ltd on Friday reported an 11.04 per cent increase in its consolidated net profit to Rs 63.96 crore for the fiscal year ended March 2023.
-
Ind-Swift Ltd launches new product in India
Ind-Swift Ltd, a leading pharmaceutical company in India, has announced the launch of its new product, XXX, in the Indian market.
-
Ind-Swift Ltd. Q3FY23 Results: Net profit declines 32% to Rs 18 crore
Pharmaceutical company Ind-Swift Ltd. reported a 32% decline in its net profit to Rs 18 crore for the third quarter ended December 2022, compared to Rs 26 crore in the same period last year. Total revenue from operations also decreased by 7% to Rs 241 crore from Rs 259 crore year-on-year.
-
Ind-Swift Ltd. to acquire Strides Pharma Science's injectables business
Ind-Swift Ltd. has entered into an agreement to acquire the injectables business of Strides Pharma Science Limited for a consideration of Rs 650 crore. The acquisition is expected to be completed by the end of March 2023.
-
Ind-Swift Ltd. launches new manufacturing facility in Himachal Pradesh
Ind-Swift Ltd. has commissioned a new state-of-the-art manufacturing facility in Himachal Pradesh. The facility will manufacture a range of pharmaceutical products, including injectables, oral solids, and ointments.